Interpace 2021 rev $41.3M (+28%), net loss improves to -$14.9M; CMS reversal on thyroid tests

INTERPACE BIOSCIENCES, INC.

2023-Q1 EPS reported -$0.53 revenue$2,454,000

Full year 2021 net revenue $41.3M, up 28% YoY; Q4 revenue $10.9M, up 13% YoY.
Net loss improved to $(14.9)M from $(26.5)M; Adjusted EBITDA $(5.1)M vs $(15.4)M.
Cash collections $43.1M, up 31%, outpacing revenue; DSO decreased 40% to 54 days.
CMS retroactively reversed Jan 2022 billing policy for ThyGeNEXT/ThyraMIR; cash collections may be delayed.
Appointed Dr. Vijay Aggarwal to board, replacing Eric B. Lev, effective Feb 1, 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.